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Abstract
Background: The targeting accuracy of proton therapy (PT) for moving soft-tissue tumours is expected to greatly
improve by real-time magnetic resonance imaging (MRI) guidance. The integration of MRI and PT at the treatment
isocenter would offer the opportunity of combining the unparalleled soft-tissue contrast and real-time imaging
capabilities of MRI with the most conformal dose distribution and best dose steering capability provided by
modern PT. However, hybrid systems for MR-integrated PT (MRiPT) have not been realized so far due to a number
of hitherto open technological challenges. In recent years, various research groups have started addressing these
challenges and exploring the technical feasibility and clinical potential of MRiPT. The aim of this contribution is to
review the different aspects of MRiPT, to report on the status quo and to identify important future research topics.
Methods: Four aspects currently under study and their future directions are discussed: modelling and experimental
investigations of electromagnetic interactions between the MRI and PT systems, integration of MRiPT workflows in
clinical facilities, proton dose calculation algorithms in magnetic fields, and MRI-only based proton treatment
planning approaches.
Conclusions: Although MRiPT is still in its infancy, significant progress on all four aspects has been made, showing
promising results that justify further efforts for research and development to be undertaken. First non-clinical
research solutions have recently been realized and are being thoroughly characterized. The prospect that first
prototype MRiPT systems for clinical use will likely exist within the next 5 to 10 years seems realistic, but requires
significant work to be performed by collaborative efforts of research groups and industrial partners.
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Introduction
Imaging represents a key concept in the treatment plan-
ning and dose delivery workflow of contemporary radi-
ation therapy. Image guided radiation therapy refers to
the visualization and quantification of geometrical un-
certainties caused by the treatment setup or changing
anatomy of the patient prior to or during dose delivery.
The role of image guidance in proton therapy (PT) has
been limited thus far [1]. Currently, in-room image guid-
ance is mainly based on 2D orthogonal X-ray imaging
and only in some centers in-room 3D computed tomog-
raphy (CT) or on-board cone-beam CT imaging is avail-
able [2]. While the latter two are expected to reduce
geometric uncertainties resulting from inter-fractional
changes in patient anatomy and treatment setup, they
provide poor soft-tissue contrast and have limited cap-
abilities for intra-fractional real-time imaging. Moreover,
X-ray imaging modalities deploy ionizing radiation
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whose exposure is associated with a long-term risk of
health effects.
Precise coverage of the target volume in PT is even
more challenging than in conventional photon-based
radiotherapy, because protons are more sensitive to
morphological variations (e.g., organ motion and de-
formation) and patient set-up inaccuracies than X-rays.
This is due to the steep dose fall-off behind the Bragg
peak and to the fact that the range of the proton beam
strongly depends on the stopping power ratio (SPR) of
a given tissue relative to water, which can be deter-
mined using the electron density and effective atomic
number through the Bethe-Bloch equation. These
uncertainties currently translate into relatively large
margins (e.g. 3.5% of the range plus an additional 2–3
mm), thus compromising the dosimetric benefit of PT
[3]. On top of the inherent uncertainties in predicting
the SPR, errors in proton range arise from tissue dens-
ity changes in the beam path due to patient setup or
anatomy differences that occur between or within treat-
ment fractions. The latter mainly relate to moving
tumours and non-stationary anatomical structures that
interact with the beam. This urges the need for real-
time image guidance during proton beam delivery.
Magnetic resonance imaging (MRI) has the ability to
offer fast real-time imaging at unparalleled high soft-
tissue contrast in the absence of ionizing radiation
exposure. With the recent clinical implementation of
real-time MR-integrated X-ray therapy (MRiXT) using
MRI in combination with Cobalt-60 sources or linear
accelerators as radiation device [4], there is a growing
interest to investigate the concept of MR-integrated
(MRiPT) as a next advancement to realize the full
clinical potential of PT [5].
The integration of MRI and PT into a hybrid system
should have an even higher potential to improve the
targeting precision of particle therapy than for X-ray
therapy. However, the following issues and open
questions have to be addressed before MRiPT can be
clinically implemented:
1. Mutual electromagnetic interactions between the
MRI and PT system may degrade the quality of the
MR image and the proton beam. The compensation
of effects from the magnetic fringe fields of the
cyclotron and beam line transport magnets onto the
magnetic fields of the MRI scanner, as well as MR-
related magnetic field effects on the beam control
and monitoring systems is challenging. As data on
these interferences are extremely scarce, and
manufacturers of both systems typically do not
specify detailed technical requirements for the
combined operation of both PT and MRI systems
in a particular setting, modelling and experimental
investigations are required to assess the impact of
these effects.
2. MRiPT requires a fast and accurate workflow for
treatment monitoring, adaptation and patient-
specific quality assurance (QA). Various approaches
for treating patients in MRiPT are conceivable. On-
line adaptive replanning for stationary tumor
indications (i.e. non-moving targets) would be an
obvious first step to exploit the improvement
offered by on-board MRI for setup verification and
detection of inter-fractional changes in anatomy.
The next stage would likely be adaptive replanning
of moving target volumes that are treated with
breath-hold gating. Ultimately, real-time MRI could
assist in the management of interplay effects during
full dynamic treatments with tumor tracking and
rescanning under free-breathing conditions.
3. Magnetic field effects on beam transport and dose
distortions of proton beams need to be taken into
account for dose calculation, optimization and
delivery. Several studies have investigated the
proton beam transport, dosimetry changes and
treatment planning in the presence of magnetic
fields, in particular the Lorentz force induced beam
deflection [6–14]. Fast and accurate dose
calculation algorithms are required together with
correction strategies to account for both the
complex-shaped magnetic fringe fields and the
uniform imaging field of the MR scanner in
treatment planning and validation of dose
measurements.
4. For online treatment planning, the dose deposition
along the proton beam path needs to be calculated
from MR images only. However, MR images do not
contain electron density information that can be
converted into SPR or water-equivalent path length
information. This has driven several research
groups to develop methods to convert MRI
information into synthetic CT information [15–20].
For real-time MR image-guided dose delivery the
conversion not only needs to be accurate but also
very fast.
Each of these four aspects is further addressed in this
article.
Experimental investigations, modelling and future
hardware requirements
Experimental investigations: proof-of-concept system
MRiPT requires the operation of an MRI scanner in an
environment contaminated by a transient electromag-
netic field of at least two origins. Firstly, the accelerating
voltage of cyclotrons and synchrotrons typically operates
in the radiofrequency range of the MR scanner.
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Secondly, fringe fields originating from dipole and
quadrupole magnets used for beam transport and focus-
sing, respectively, as well as from fast-switching dipole
magnets used for beam scanning in the nozzle could
change the magnetic field homogeneity and resonance
frequency during MR image acquisition, leading to
severe image artifacts. Conversely, the static and dy-
namic MR fringe fields might impact the beam steering
and control system. Ionization chambers at the beam
line nozzle get exposed to the fringe fields of the MRI
scanner as well as to high acoustic pressure levels gener-
ated by the MRI scanner during image acquisition. To
compensate for these effects new shielding measures and
image acquisition schemes might be necessary to be
developed.
Recently, for the first time a proof-of-concept study
was realized within a research program at OncoRay in
Dresden, combining a C-shaped 0.22 T open MRI scan-
ner with a horizontal static proton research beam line
[21]. Prior to installation of the MRI scanner into the
experimental room of the clinical proton therapy facility,
the authors conducted a magnetic survey. Tri-axial
magnetometry showed an increase in the environmental
magnetic field at the beam isocenter that is in the
micro-Tesla range when the beam transport magnets
were energized for 70–220MeV beams. During a full
360° gantry rotation in the adjacent treatment room, a
sub-micro-Tesla change in environmental magnetic field
was measured in all three field components nearby the
beam isocenter. Measurements with a magnetic field
camera positioned at the magnetic isocenter of the MRI
scanner showed minor changes in its static magnetic
field and no effects on the magnetic field homogeneity
when the beam transport magnets were energized for
different beam energies. From these measurements, no
severe MR image degradations were expected, and hence
no additional magnetic shielding was applied. First MR
images of tissue-mimicking phantoms have been ac-
quired with this in-beam MRI scanner during proton
beam irradiation. No MR image degradation was
observed when images were acquired during constant
operation of the beam line. No visible beam-induced
effects were reported.
For a more clinically realistic setting, the technical in-
tegration with a pencil beam scanning (PBS) beam line
is currently under investigation, as the influence of the
scanning magnets is expected to be larger than that of
the beam line magnets [22]. In-silico modelling of a PBS
scenario is further presented in the next section.
Modelling of magnetic interactions between MRI scanner
and PT delivery system
Finite element (magnetic field) and Monte Carlo (radi-
ation transport) modelling methods can be used to
investigate the key interactions in a potential MRiPT
system. To the best of our knowledge, only one such study
exists in the literature [23]. This study presents as an ex-
ample a model of the 1 T split-bore MRI system of the
Australian MRI-Linac programme and a typical PBS as-
sembly (Ion Beam Applications SA, Louvain-la-Neuve,
Belgium) used for delivering therapeutic proton beams.
COMSOL Multiphysics® (COMSOL AB, Stockholm,
Sweden) models the MRI system and the PBS system from
first principles. The PBS system has been modelled to
emulate a dynamic PBS pattern (Fig. 1). The variation in
magnetic field homogeneity (MFH, in parts per million,
ppm) of the imaging volume was evaluated on a 30 cm
diameter spherical volume as a function of the scanning
pattern. By importing the magnetic field maps into
Geant4, the Monte Carlo simulations showed how the
scanned pencil beam is deflected and distorted by the
presence of the magnetic field.
This integrated simulation approach allows to study
(1) the impact of the PBS scanning on the MFH, and (2)
the deflection of the proton trajectories as they reach the
treatment volume. Typically, the MFH should be a few
ppm for minimal image distortion and not change with
time. The simulation results show a dynamic change in
peak-to-peak MFH of < 2 ppm with an offset of 56.5
ppm. The static change to the MFH is beam energy
dependent and would be correctable by passive or active
shimming of the MR magnet. Experimental and Monte
Carlo phantom studies have consistently shown predic-
able magnetic field-induced beam deflections in phan-
tom geometries [24]. Furthermore, Monte Carlo based
treatment planning studies on patients have demon-
strated that dose distortions are generally negligible for
magnetic field strengths up to 0.5 T (except for prostate)
and correctable for up to 1.5 T (Fig. 2) [8–10]. Due to
the near and far magnetic fringe fields, the proton pencil
beam paths exhibit a rotation around the central beam
axis. Such a change is expected to be addressed using
software-based correction methods [5].
Future hardware requirements
For MRiPT to be clinically viable, the treatment options
should not be significantly compromised as compared to
existing PT. In case of MRiXT, compromises were made
in terms of: loss of couch angle, large couch shifts,
VMAT techniques and collimator rotation. Also, with
the Elekta Unity system the X-ray beam is transmitted
through the aluminium cryostat of the MRI scanner,
which lowers the dose rate. The following sections detail
the key requirements expected in future MRiPT systems.
Magnet design
The magnet design either needs to be open or split-bore
style, such that the proton beam has direct access to the
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Fig. 1 Model of the magnetic interaction between an MRI and PBS assembly when delivering a scanning pattern down the bore of the MRI.
Example of a scanned pencil beam with the MRI scanner turned off (a) and on (b). c Scanning magnet (SM) settings and MFH over the scanning
pattern shown in (d). e Changes to the scanning pattern due to the presence of the magnetic field from the MRI scanner
Fig. 2 Proton dose distortions within uniform transverse magnetic field of 0.5 T (a), 1.5 T (b), and 1.5 T with delivery corrections (c), for a prostate
plan (i.e. large range representing the worst-case scenario). d Dose volume histogram for the 3 above scenarios with the magnetic field on,
compared to the planned dose with no magnetic field. Adapted from [8]
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patient. For best practice, at least a partial gantry (e.g.
220° rotation) is required for beam access from any gan-
try angle (when coupled with a reversible patient couch).
A prototype system that features an almost complete
split-gap is well suited to allow a proton beam to reach
the patient from all gantry angles. Here, the beam direc-
tion would be perpendicular to the main magnetic field
[5]. Alternatively, an open magnet design with a C-
shaped or U-shaped rotating magnet could be integrated
in the proton gantry, which requires the beam to pass
through one of the magnet poles (see Fig. 3).
MR-compatible couches
Treatment couches that are MR safe already exist in
MRiXT. For MRiPT, typically couches with 6 degrees of
freedom (6DOF) are used. However, such robotic
couches are not MR compatible, and hence need to be
modified accordingly. The 6DOF nature is highly advan-
tageous for online adaptive therapy as a simple patient
translation or rotation is performed more easily than a
complete adaptive replanning based on a new patient
position.
Gantry modifications
With MRiXT systems, the MRI scanner has been the
most important structure to preserve. Adoption of the
linear accelerators have been achieved through novel
gantry rings that take advantage of the magnet design
and housing. For MRiPT, it is expected that the integra-
tion of the MRI scanner is less obvious than for MRiXT.
Magnetic decoupling of the PBS beam line from the
MRI is mandatory and technically challenging. It would
be natural to expect some form of additional magnetic
shielding or active decoupling between the beam line
and MRI. Due to the already large amount of steel com-
ponents in beam lines, it could be envisaged that clever
designs may utilise or modify the existing gantry struc-
tures to in fact assist or perform some of the magnetic
decoupling process. Magnetic modelling will be key in
ascertaining the effectiveness of any such approaches.
Integration into clinical facilities
Before MRiPT can be integrated into clinical facilities, a
number of technical aspects need to be addressed to
make sure that the performance of a fully integrated sys-
tem meets the clinical expectations. The entire purpose
of integrated MR and PT is to be able to perform online
adaptive treatments. Hence a robust workflow needs to
be established which delivers that promise. In order to
achieve this, fast and accurate dose calculation and plan-
ning methods need to be deployed with corresponding
fast processing of the integrated MR images. Having the
daily patient imaging natively as MR based introduces
further complexities, in particular for PT. However an
MRI-only based approach would be advantageous. The
following sections describe these key elements in greater
detail.
Treatment workflow: online adaptation
Similar to the clinical introduction of MRiXT in 2014
(MRIdian by ViewRay) and 2018 (Unity by Elekta), treat-
ment centres will be required to commence with a new
and dedicated workflow that is specific to the MRiPT
system. In a nutshell, the patient’s anatomy at pre-
fraction imaging will be assessed and compared with the
planning anatomy; the default plan will be calculated on
the new patient dataset and the dose differences evalu-
ated. If the original dose constraints are met, then treat-
ment would continue as normal. However in the event
of a failure, adaptive replanning would be invoked. For
adaptive replanning, the approach is essentially the same
as that for MRiXT, however several components are not-
ably more complicated and potentially sensitive to the
Fig. 3 Artist impressions of (a) a rotating biplanar open in-beam MRI
scanner integrated in a (b) compact proton therapy gantry
treatment room (Image courtesy: Ion Beam Applications
SA, Louvain-la-Neuve, Belgium)
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overall accuracy of the treatment. These include proton
beam dose calculations in magnetic fields and the use of
MR-only planning.
Plan adaptation method
The adaptation process for online adaptive treatments
will be most accurately completed using full plan reopti-
mization. This includes calculating a new series of beam-
lets for the new patient anatomy and optimizing their
distribution and weighting to achieve the desired dose
constraints. The calculation of beamlets is however a
parallelizable process as each is independent of the
other, and so will benefit directly with multiple thread
processing. Once generated, an optimizer will produce
plans and the robustness can be assessed. More details
on the calculation of proton beamlet in the context of
being subject to magnetic fields are provided later on.
Gated treatment delivery
Gated treatments could be expected as the default treat-
ment style. In this scenario the real-time MR informa-
tion is used to confirm that the patient position has not
changed significantly and that beam-on can continue as
normal. For this, fast time-resolved 2D-cine MRI in a
plane perpendicular to the beam direction is required
[25, 26]. The MR image acquisition, reconstruction and
post-processing must be fast (i.e. > 4 frames/sec) and
seamlessly integrated into the software of the hybrid
MRiPT system. Current MRiXT systems are reporting
this process to be feasible even up to 4 frames/sec [27].
Dynamic treatment delivery
For tumours that move, real-time motion mitigation
could be achieved through synchronizing the dynamic
MR images with the beam control system to enable
tumour tracking in real time. The system latency time
can be minimized with the aid of motion prediction
models. In the case of MRiXT, Glitzer et al. [28] de-
scribes the latencies of the MLC for real-time tracking
being as small as 204 ms at 8 Hz imaging rate. For
MRiPT, simple lateral tumour motion (relative the beam
direction) could be in principle tracked dynamically by
globally shifting the PBS delivery pattern. This would
require a modified PBS controller that can superimpose
a shift to the scanning currents as they are being set.
However, depending on the changes of the traversed
anatomy, and in the more realistic case of true 3D
tumour motion, dynamic tracking may not be feasible
due to the degradation of the dose coverage. This is a
problem unique to PT as the Bragg peak positions
depend on radiological depth, thus also requesting
adjustment of the beam energy in addition to the beam
lateral position. Detailed modelling and planning studies
will ultimately help determine if dynamic treatments are
feasible for a given patient anatomy and tumour motion.
Adaptive replan quality assurance
It will be a key requirement to perform an independent
check of the integrity of a new adaptive patient plan.
With the patient waiting on the treatment couch, this
process needs to be as fast as possible. The most obvious
and attractive method to achieve this will be through a
dedicated independent secondary dose calculation. At
present, MRiXT treatments perform this process by
recalculating the dose from the new treatment plan
using alternate software with different calculation
algorithms. The results are compared with the primary
TPS prediction and the accuracy of the match is
assessed. It is highly likely that this approach will be
taken with MRiPT. Careful end-to-end validation of the
workflow will ensure adequate performance. Maximizing
the workflow automation could lead to higher accuracy,
shorter treatment times, and increased patient
throughput.
Most recently, artificial intelligence (AI) has been
helpful in adaptive replanning for MRiXT through an
automatic MRI segmentation method using convolu-
tional neural network (CNN) based correction networks
[29, 30]. As these steps of the online adaptive workflow
will be identical between MRiXT and MRiPT, we expect
such AI methods to be applicable for MRiPT as well.
Dose calculation algorithms in magnetic fields
In MRiPT, therapeutic proton beams are subject to
Lorentz forces when being transported from the PBS as-
sembly to the patient at the imaging center of the MR
scanner, as well as when being transported to the treat-
ment volume within the patient. Hence, both the non-
uniform magnetic fringe field between the PBS assembly
and the MR imaging center and the uniform imaging
field have to be considered during the dose calculation
process.
The pencil beam transport within the treatment
volume in the presence of a magnetic field has been sim-
ulated in different Monte Carlo environments. Generally,
the magnetic forces are calculated at each step of the in-
tegration by solving the relativistic Lorentz equation for
the charged particle while it loses energy during penetra-
tion. For example, in [6] and [10] Geant4 was used to
investigate proton dose effects of transverse magnetic
fields in water phantoms and patient geometries, re-
spectively. In [12] GATE based on Geant4 was used to
study proton and carbon ion beam transportation in
magnetic fields between 0 to 3 T (Fig. 4). In [9] the TOol
for PArticle Simulation (TOPAS) [31], which is also
based on Geant4, was used to show the dosimetric feasi-
bility of intensity modulated proton therapy (IMPT) plan
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optimization using PBS in a transverse magnetic field of
1.5 T. In [10], IMPT plan optimization using PBS in the
presence of a 1.5 T magnetic field was implemented
using Geant4 based dose calculations to show that the
robustness of the prostate cancer treatment plans against
interfractional anatomical changes and positioning er-
rors is similar to the scenario without magnetic field in
case the treatment parameters were judiciously adjusted.
TOPAS was also used in a treatment planning study,
which confirmed the dosimetric feasibility of MRiPT for
various tumor locations using passive scattering beam
delivery [8]. Although such general-purpose Monte
Carlo codes deliver high-precision simulations, the main
drawback is a computation time in the order of hours
needed to perform simulations when low statistical
uncertainty is necessary [32]. This is due to the detailed
simulation of physics processes, especially the nuclear
interactions [33, 34]. Meanwhile, fast Monte Carlo codes
suitable for medical applications have been developed
and it has been shown that this amount of details is not
always necessary [35, 36]. Recently, the fast Monte Carlo
software MCsquare [37] has been extended to include
the effects of interactions between protons and an exter-
nal uniform magnetic field. This implementation
achieves computation times in the order of minutes and
was experimentally validated comparing simulations and
measurements of 150MeV protons through an electro-
magnet with maximum magnetic intensities from 0.5 to
1 T [38]. The speed of the dose calculation algorithm
might become an essential feature in sight of real-time
adaptive 4D applications foreseen for MRiPT. Final re-
quirements for proton dose calculations in magnetic
fields and MRI-only based treatment planning will
depend on how MRiPT will be used clinical workflow
(e.g. off-line adaptations or online daily adaptations).
Corresponding requirements for treatment planning of
MRgXT have been reported and discussed in [39].
Two approaches have been discussed to address the
influence of the magnetic fringe field on proton pencil
beam transport. One option is to use a dedicated look-
up-table for a specific MRiPT design, containing (mea-
sured) deflections of pencil beams with various energies
when entering the treatment volume [5]. Alternatively,
the protons can be transported through a 3D magnetic
field map of a specific MRiPT design, considering deflec-
tions in each transportation step, equally through the
non-uniform fringe field as when entering the uniform
MR imaging field. A combination of both approaches
seems to be most promising: using look-up tables to ac-
count for beam offsets further away from the patient,
while relying on detailed 3D magnetic field maps for the
non-uniform fields close to the MR scanner and patient.
Most MRiPT planning studies published so far neglect
the influence of fringe fields and only investigate the im-
pact of the imaging field component. A first planning
study incorporating the fringe field component has re-
cently been presented [40].
As mentioned above, computational speed is an essen-
tial feature for dose calculation. Despite dedicated clin-
ical Monte Carlo dose engines for proton beam therapy,
optimization and pre-calculations are often still
performed with pencil beam algorithms due to their
superior speed and reasonable accuracy [41]. The first
pencil beam algorithms for MRiPT was based solely on
an analytical approximation of the Bragg peak and beam
deflection due to the magnetic field [7]. Most current
pencil beam algorithms rely on look-up tables to enable
a better tuning towards measurement data. Especially for
larger beam deflections, the penetration depth is also
affected, leading to a retraction of the Bragg peak [12,
Fig. 4 Calculated two-dimensional relative dose distribution for a 240 MeV proton beam in a homogeneous water phantom within a transverse
3 T magnetic field
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13]. To compensate for this effect and to account for
magnetic fringe fields, deflection calculation based on
numerical solution of the relativistic Lorentz equation,
similar to Monte Carlo codes, was integrated [12–14].
For high magnetic field strengths, depending on the
energy distribution of the delivery system, additional ef-
fects, such as the deformation of the Bragg peak due to
spectroscopic effects may need to be accounted for.
Validation of dose calculations in the presence of a
magnetic field using a clinical TPS as well as compre-
hensive treatment planning studies are lacking so far.
The development and validation of TPS software enab-
ling proton beam transport through magnetic fields will
follow once clinical prototypes of MRiPT units become
available. The Monte Carlo solutions being introduced
by vendors of TPS systems would lend themselves to be
integrated with 3D magnetic field maps of MRiPT
systems.
MR-only based proton therapy planning
MRI-to-CT conversion techniques for enabling dose
calculation and treatment planning can be grouped into
four, often combined categories: (1) bulk density over-
ride; (2) atlas-based; (3) voxel-based and (4) deep learn-
ing techniques. Besides direct MR-to-CT conversion
(MR-only) approaches, CT-to-MRI deformable image
registration based approaches have been discussed [42–
45]. For MR-only based photon therapy planning, exten-
sive research has been performed and discussed in re-
cent reviews [46, 47]. However, a limited number of
contributions exist for MR-only based proton treatment
planning (see Table 1), which requires a higher Houns-
field unit (HU) accuracy. One major problem is to separ-
ate and predict the correct bone and air HU values on
the generated pseudo or synthetic CT (sCT) images.
For this reason, first MRI-to-CT approaches used
highly specialized MR sequences, such as ultra-short
echo time (UTE). Rank et al. [15] employed 2D turbo
spin echo (TSE) with proton density weighting and 3D
UTE sequences in combination with a tissue classifica-
tion approach for MRI-to-CT conversion in the brain re-
gion. Comparably large errors were observed for bone
and air regions with a mean absolute error (MAE) of
145 HU. Dosimetric comparisons of proton and carbon
ion treatment plans yielded deviations in the planning
target volume (PTV) of 0.4–2.0%. Also Edmund et al.
[17] evaluated MRI-to-CT conversion in five brain pa-
tients using two UTE (flip angles 10° and 25°) and a
standard T1-weigthed image. Conversion was performed
using six voxel-based approaches. The best results were
obtained for statistical regression: MAE = 128 HU and
mean error (ME) = 8 HU. Analysis of the dose-volume
histogram (DVH) and the generalized equivalent
uniform dose (gEUD) for tumor and brainstem showed
deviations within 2%.
In contrast to these UTE based methods, Koivula et al.
[18] employed a single T1/T2*-weighted dual gradient
echo MRI sequence. sCT images were generated by
manual delineation of bone and soft tissue on the MR
images, followed by the application of two site-specific
MRI-to-CT conversion models [53]. Proton dose calcu-
lation accuracy was evaluated for 10 prostate and 10
Table 1 Overview of synthetic CT generation methods applied to patient data and evaluated for proton therapy dose calculations
Body site Method MRI pulse sequence Conversion time MAE in HU Dose accuracy Study
Brain Voxel-based classification 2D TSE, 3D UTE 300 s 145 ΔDVH < 2% [15, 16]
Brain Voxel-based classification UTE, T1w n.a. 128 ΔDVH < 2% [17]
Brain Voxel-based classification T1w, T2w 205 s 124 ΔDVH < 0.5 Gy
Γ2%2mm = 98%
[20]
Brain Deep learning T1w 30 s 54 ΔRange = 0.14 ± 1.11% [48]
Brain Deep learning T1w 2 s (2D)
12 s (3D)
82–135 (2D)
82–147 (3D)
Γ2%2mm = 98% (2D)
Γ2%2mm = 97% (3D)
[49]
Brain
Prostate
Voxel-based classification T1/T2*w dual gradient echo 30 s 42 (brain)
a
34 (prostate)a
ΔDVH < 1.4%
Γ2%2mm = 99%
[18]
Prostate Bulk assignment 3D dual spoiled gradient echo 120 s 83 ΔDVH < 2%/2 Gy
Γ2%2mm = 98%
[19]
Prostate Bulk assignment 3D dual spoiled gradient echo 120 s 81 Mean ΔDVH = 0.6%/1.5 Gy
Γ2%2mm = 93%
[50]
Abdomen
Pediatric
Voxel-based classification T2w TSE 195 s 212 (bone)
125 (lung)
52 (soft tissue)
ΔDVH < 4%
Γ2%2mm = 88%
[51]
Liver Deep learning T1w 120 s 73 ΔDVH < 1%
Γ2%2mm = 97%
[52]
Abbreviations: TSE turbo spin echo, UTE ultra-short echo time, T1w T1-weighted, T2w T2-weighted, ΔDVH change in dose-volume histogram parameters, Γ2%2mm 2%,
2 mm gamma criterion, ΔRange change in proton range
ain pre-selected regions of interest
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brain cases using robust planning. For a (2%, 2 mm)
gamma analysis criterion (10% threshold), average pass-
rates of 98.6 and 99.5% were obtained for pelvis and
head. DVH parameters for the clinical target volume
were within 0.6 and 1.4%, respectively. The MAEs in
pre-selected volumes-of-interest were 42 HU and 34
HU. Guerreiro et al. [51] extended the methodology for
application to 30 pediatric patients with abdominal
tumors. A third tissue class (lung) was added and delin-
eation of bone, soft tissue and lung was automated by
atlas-based segmentation. Similar to [18], internal gas
pockets were not identified on the used T2-weighted
TSE images. For the same gamma criterion, an average
pass-rate of 88.1% was reported for robustly optimized
IMPT plans after body contour and internal air cavity
matching with a reference CT. Differences in DVH pa-
rameters for the internal target volume were below 1%,
for organ-at-risk (OAR) deviations up to 4% occurred
due to considerable inter-scan differences. Average
MAEs of 212 HU, 125 HU and 53 HU were reported for
bone, lung and soft tissue, respectively.
A commercial certified photon-oriented sCT gener-
ation method (MRCAT [54]) was adapted and evaluated
in the scope of PT by Maspero et al. [19]. The method
employs a dual spoiled gradient echo sequence and
Dixon reconstruction, in combination with a constrained
shape bone model and bulk density assignment of 5 tis-
sue classes for sCT generation. It was extended to allow
for the identification of internal gas pockets. A MAE of
83 HU was reported. Using fully modulated IMPT plans,
an average (2%, 2 mm) gamma pass-rate of 98.4% was
obtained after matching of internal cavities and body
outlines. DVH parameters for targets and OARs were
within about 2 Gy or 2%. The median range difference
Fig. 5 a From left to right: HU and dose profile of a proton spread-out Bragg peak (SOBP) for a beam entering via the frontal sinus. SOBP dose
and dose difference distribution in a 2D sagittal plane as planned on the sCT and then delivered on the CT using a prescribed dose of 2 Gy.
Adapted from [48]. b Original MRI, CT and pseudoCTs generated with a 2D and a 3D Unet for an exemplary brain case. The SFUD proton dose
distribution for a single gantry angle is depicted on the original CT and the two pseudoCTs. The generic target volume is marked in red, the 95%
iso-dose line in green. Adapted from [49]
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for single-field-uniform-dose (SFUD) proton plans was
0.1 mm. Using the same method (without identification
of internal air cavities), Depauw et al. [50] also con-
cluded that, based on DVH parameter analysis, clinically
acceptable proton dose calculation accuracy can be
achieved. Also Pileggi et al. [20] performed sCT gener-
ation for 14 patients in the brain region using standard
T1- and T2-weighted MRI in combination with a look-
up table. Image analysis yielded an MAE of 124 HU.
Median range shifts were 0.5 mm and the average (2%, 2
mm) gamma pass-rate was 98%. The worst DVH differ-
ence was 0.5 Gy.
In [48], for the first time a deep learning approach (U-
shaped convolutional neural network [Unet]) was tested
for sCT generation in PT. 15 patients with simulated tu-
mors in the brain were planned to receive three SFUD
plans (Fig. 5a). Average MAEs of 53 HU (air), 44 HU
(fat), 10 HU (cerebrospinal fluid), 6 HU (white matter),
8 HU (gray matter), 119 (bone) and 54 HU (entire field
of view) were determined. The relative proton range
error was 0.14 ± 1.11%. In parallel, Neppl et al. [49] in-
vestigated the feasibility of utilizing deep 2D and 3D
Unets for sCT generation of the head (Fig. 5b). MAE
ranged from 82 to 135 HU for the 2D and from 82 to
147 HU for the 3D Unet. For SFUD proton plans, a (2%,
2 mm) gamma evaluation yielded average pass-rates of
98 and 97% for the 2D and 3D Unet. On average, more
than 90% of all depth dose profiles had a range agree-
ment better than 2 mm for both Unets. An alternative
network design (3D cycle-consistent generative adversar-
ial network) was used by Liu et al. [52] for sCT gener-
ation in the liver region using a cohort of 21 patients.
An average MAE of 72.87 ± 18.16 HU was reported. In
a two-proton-beam set-up, DVH deviations in the PTV
below 1%, and an average (2%,2 mm) gamma pass-rate
of 97% were reported. The mean range deviation was
below 2mm.
In summary, although none of the presented ap-
proaches was yet translated into the clinic in the scope
of MR-only based PT, they generally showed promising
results for various tumour sites, with clinically accept-
able deviations from reference CT images. While initial
studies focused on the use of dedicated MRI sequences
for air and bone separation (e.g., UTE), more recent ap-
proaches aimed at utilizing standard MRI sequences
(e.g., T1w) to facilitate clinical adoption. This trend
could also enable usage of sequences less prone to geo-
metric distortions (e.g., at the patient outline), which is
important for accurate proton dose estimation. In terms
of conversion technique, the research focus is shifting
more to the application of deep learning techniques,
which can theoretically handle arbitrary MRI sequences
as input and provide accurate sCTs with continuous HU
values in very short (~seconds) times, thus fulfilling the
time requirements of MR-only workflows for online
adaptive MRiPT.
Discussion and conclusions
For moving target volumes the need for real-time image
guidance in proton therapy is of even greater importance
than for photon therapy. Given the successful develop-
ment of different types of MR-integrated X-ray therapy
devices, and the increasing clinical interest to apply
them for the treatment of moving targets of soft tissues
that are difficult to visualize with conventional X-ray
based imaging modalities (e.g. prostate, cervix, colorec-
tum, esophagus, liver, pancreas), it would be a logical
next step to develop a similar MR-integrated concept for
proton therapy. Although MRiPT is still in its infancy,
several research groups have started addressing the
major technical challenges and developments required
for bringing this concept into clinical reality. Substantial
progress has been made to uncover and understand the
magnetic interactions between the MRI and PT system
that affect both image and beam quality, predict and
measure dosimetric effects due to the magnetic fields
with high accuracy, optimize IMPT dose distributions in
the presence of magnetic fields, and calculate dose distri-
butions directly from MRI information for an MRI-only
based adaptive workflow. Results from these efforts are
promising and offer the prospect that the development
of prototype MRiPT systems within the next 5 to 10
years should not be considered beyond the realms of
possibility. To bring the MRiPT concept to the clinic,
improvements in both hardware and software are re-
quired. The magnet design must be optimized for the
intended treatments, and magnetic decoupling from the
PBS beam line needs to be established. Fast software
methods are needed for dose calculation and
optimization in magnetic fields. For online adaptive re-
planning, fast and accurate MRI-only based treatment
planning methods need to be developed and validated
against current clinical standards, including the gener-
ation of reliable pseudo or synthetic CT. Here, the
accuracy required for safe clinical implementation of
MR-only based proton therapy planning is still debatable
and might be defined individually at institutional level,
e.g., by comparison of potential sCT inaccuracies to the
applied clinical margins, the accepted dosimetric uncer-
tainties, and the assumed uncertainties for CT-number
to stopping power conversion. Ultimately, the methods
need to be tested against the low-level uncertainty
offered by proton beam range calculations based on
dual-energy or proton CT images [55, 56]. Clinical
adopters might have to balance the advantages of pre-
treatment and/or online imaging at high soft-tissue con-
trast, possibly followed by treatment adaptation, against
a potential loss in accuracy for stopping power
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prediction. This trade-off will likely depend on the treat-
ment site, meaning that entities affected by pronounced
inter- and intra-fractional changes are more likely to
benefit from MRiPT. Furthermore, the development of
MRI sequences allowing for the extraction of specific tis-
sue properties (i.e., electron density, stopping power,
elemental composition, water-equivalent path length) is
a future research direction.
Finally, significant work needs to be performed to de-
velop simple gantry-less prototype MRiPT systems that
have the potential to be fully integrated with gantries at
a later stage. This development would significantly im-
prove the quality of proton therapy, in particular for
moving tumours, and furthermore has the potential to
outperform the present indications for high-precision
stereotactic irradiation with MRiXT.
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